Core Viewpoint - Taylor Morrison Home Corporation announced the expiration of its cash tender offer for its outstanding 5.875% Senior Notes due 2027, which took place from November 3 to November 7, 2025, with valid tenders amounting to approximately $479.155 million, representing 95.83% of the total outstanding amount of $500 million [1][3][4]. Group 1: Tender Offer Details - The cash tender offer was initiated by Taylor Morrison Communities, Inc., a wholly owned subsidiary of Taylor Morrison Home Corporation [1]. - The expiration time for the tender offer was set for 5:00 p.m. New York City time on November 7, 2025 [1]. - The purchase price for the validly tendered notes was set at $1,023.07 per $1,000 principal amount [3]. Group 2: Financial Implications - The Offeror plans to use a portion of the proceeds from a new issuance of $525 million aggregate principal amount of 5.750% senior notes due 2032 to fund the payment for the notes purchased in the tender offer [4]. - Payment for the validly tendered notes is expected to occur on November 10, 2025 [4]. Group 3: Future Actions - Following the settlement of the tender offer, the Offeror intends to redeem any outstanding notes that were not purchased [5]. - A conditional notice of redemption has been issued for any remaining notes, with a target redemption date around December 2, 2025, contingent upon receiving sufficient funds from the senior notes offering [5]. Group 4: Company Background - Taylor Morrison is recognized as one of the leading homebuilders and developers in the United States, serving a diverse range of consumers across various market segments [8].

Core Viewpoint - Nurix Therapeutics, Inc. successfully closed an underwritten registered offering of 24,485,799 shares at $10.21 per share, raising gross proceeds of $250 million to fund clinical development and research activities [1][4]. Group 1: Offering Details - The offering included participation from both new and existing investors, highlighting strong support for the company's mission [2]. - J.P. Morgan Securities LLC, Jefferies LLC, and Stifel, Nicolaus & Company acted as joint book-running managers for the offering [3]. - The securities were offered under a shelf registration statement previously filed with the SEC [5]. Group 2: Use of Proceeds - The net proceeds will primarily fund the clinical development of bexobrutideg (NX-5948) for chronic lymphocytic leukemia (CLL) and explore potential autoimmune indications [4]. - Additional funds will support research and development activities to expand the pipeline and cover working capital and general corporate purposes [4]. Group 3: Company Overview - Nurix Therapeutics focuses on targeted protein degradation medicines for oncology and autoimmune diseases, with a pipeline that includes degraders of Bruton's tyrosine kinase (BTK) [8][9]. - The company is advancing multiple potentially first-in-class or best-in-class drug candidates and has collaborations with major pharmaceutical companies like Sanofi and Gilead [8][9].

Core Viewpoint - Nurix Therapeutics, Inc. has announced the pricing of its underwritten registered offering of 24,485,799 shares at $10.21 per share, aiming to raise approximately $250 million for clinical development and research activities [1][4]. Group 1: Offering Details - The offering consists of 24,485,799 shares priced at $10.21 each, with expected gross proceeds of $250 million before expenses [1]. - The offering is set to close on or about October 23, 2025, pending customary closing conditions [1]. - Participation in the offering includes both new and existing investors such as General Atlantic and Redmile Group [2]. Group 2: Use of Proceeds - Nurix intends to use the net proceeds primarily for clinical development of drug candidates, including bexobrutideg (NX-5948) for chronic lymphocytic leukemia (CLL) and potential autoimmune indications [4]. - Additional uses include funding research and development to expand the pipeline, as well as for working capital and general corporate purposes [4]. Group 3: Management and Registration - J.P. Morgan Securities LLC, Jefferies LLC, and Stifel, Nicolaus & Company are acting as joint book-running managers for the offering [3]. - The offering is made under a shelf registration statement previously filed with the SEC, which was declared effective on June 11, 2024 [5].

Group 1 - Carlyle has priced an offering of $800 million aggregate principal amount of 5.050% senior notes due 2035, which will be fully guaranteed by its indirect subsidiaries [1] - The offering is expected to close on September 19, 2025, subject to customary closing conditions, and the net proceeds will be used for general corporate purposes [1] - The offering is made under an effective shelf registration statement on file with the U.S. Securities and Exchange Commission [3] Group 2 - The joint book-running managers for the offering include Citigroup Global Markets Inc., Goldman Sachs & Co. LLC, J.P. Morgan Securities LLC, Morgan Stanley & Co. LLC, and Wells Fargo Securities, LLC [2] - Carlyle is a global investment firm with $465 billion of assets under management as of June 30, 2025, and operates across three business segments: Global Private Equity, Global Credit, and Carlyle AlpInvest [5] - The firm employs over 2,300 people in 27 offices across four continents, focusing on investing wisely and creating value for its investors and communities [5]

Core Viewpoint - Carlyle, a global investment firm, announced its intention to offer senior notes, which will be guaranteed by its indirect subsidiaries, with proceeds intended for general corporate purposes [1][5]. Group 1: Offering Details - The offering of senior notes is subject to market and other conditions [1]. - The offering is being managed by Citigroup Global Markets Inc., Goldman Sachs & Co. LLC, J.P. Morgan Securities LLC, Morgan Stanley & Co. LLC, and Wells Fargo Securities, LLC as joint book-running managers [2]. - The offering is made under an effective shelf registration statement filed with the U.S. Securities and Exchange Commission (SEC) [3]. Group 2: Company Overview - Carlyle manages $465 billion in assets as of June 30, 2025, and operates across three business segments: Global Private Equity, Global Credit, and Carlyle AlpInvest [5]. - The firm employs over 2,300 people in 27 offices worldwide [5].

Core Viewpoint - MPLX LP has successfully priced $4.5 billion in unsecured senior notes to fund acquisitions and general partnership purposes [1][2]. Group 1: Offering Details - The offering consists of four tranches: $1.25 billion of 4.800% senior notes due 2031, $750 million of 5.000% senior notes due 2033, $1.5 billion of 5.400% senior notes due 2035, and $1.0 billion of 6.200% senior notes due 2055 [1]. - The closing of the offering is expected on August 11, 2025, pending customary closing conditions [3]. Group 2: Use of Proceeds - A portion of the net proceeds will fund the acquisition of Northwind Delaware Holdings LLC and cover related fees and expenses [2]. - The remaining proceeds will be used for general partnership purposes, including capital expenditures and working capital [2]. Group 3: Company Overview - MPLX is a diversified, large-cap master limited partnership that operates midstream energy infrastructure and logistics assets, including pipelines, terminals, and storage facilities [6].

Core Viewpoint - Gerdau S.A. has completed its offer to purchase outstanding 4.875% notes due 2027, with all validly tendered notes accepted for purchase [1][3]. Offer Details - The offer was made for cash to purchase all outstanding 4.875% notes due 2027, guaranteed by Gerdau and its subsidiaries [1]. - The offer expired on June 9, 2025, at 5:00 p.m. New York City time [3]. - A total principal amount of US$418,244,000 was outstanding, with US$237,646,000 tendered [2]. - The consideration for the notes accepted was US$1,007.83 per US$1,000 principal amount [2]. Settlement Information - Settlement of the offer is expected to occur within three business days following the expiration date, specifically on June 12, 2025 [4]. Additional Information - Gerdau Trade has engaged several financial institutions, including BofA Securities, Goldman Sachs, J.P. Morgan, and Morgan Stanley, to act as dealer managers for the offer [6]. - Further details regarding the offer can be found in the Offer Documents available through the designated tender agent [5].

Core Viewpoint - Cellebrite has announced its agreement to acquire Corellium for an enterprise value of $170 million in cash, enhancing its capabilities in digital investigations and security for smart devices [2][3] Company Overview - Cellebrite is a global leader in digital investigative solutions, focusing on enhancing digital investigations and intelligence gathering to accelerate justice [6] - Corellium specializes in Arm hypervisor virtualization, providing solutions for security and developer teams to build, test, and secure software for mobile, automotive, and IoT devices [7] Acquisition Details - The acquisition is valued at $170 million, with $20 million converted to equity at closing, and an additional $30 million contingent on performance milestones over the next two years [2] - The deal is expected to close in summer 2025, pending approval from the Committee on Foreign Investment in the United States [2] Strategic Benefits - The combination of Cellebrite and Corellium is expected to set a new standard for digital investigations and enhance the security of Arm-based devices across various applications [1] - Corellium's technology will broaden Cellebrite's Total Addressable Market (TAM) in both public and private sectors, enhancing its Digital Investigation Platform and mobile vulnerability research capabilities [1][2] Technological Advancements - The acquisition will enable accelerated identification of mobile vulnerabilities and exploits, and provide an industry-first ability to visualize and interact with virtual devices [4] - Corellium's virtualization platform will enhance DevSecOps efficiency across all Arm-based devices, facilitating the development of high-performance, secure mobile applications and IoT devices [4][1]

Core Viewpoint - Gerdau S.A. has initiated a cash offer to purchase all outstanding 4.875% notes due 2027, totaling approximately US$418.24 million, which are guaranteed by its subsidiaries [1][3]. Offer Details - The offer is set to expire on June 9, 2025, at 5:00 p.m. New York City time, unless extended or terminated earlier by Gerdau Trade [3]. - Holders of the notes who validly tender their notes by the expiration date will be eligible to receive the consideration, which will be determined based on a fixed spread plus the yield of a reference U.S. Treasury security [4][5]. - Settlement of the offer is expected to occur within three business days following the expiration date, anticipated to be June 12, 2025 [6]. Conditions and Rights - The acceptance of the notes is contingent upon the successful pricing of a debt offering by Gerdau Trade, generating sufficient net proceeds to cover the consideration and accrued coupon payments [8]. - Gerdau Trade reserves the right to delay acceptance, extend the expiration date, or terminate the offer if conditions are not met [9][10]. - The offer is not conditioned on a minimum amount of notes being tendered, and if terminated, no payments will be made to holders of the notes [10]. Subsequent Actions - After the expiration date, Gerdau Trade may acquire any remaining notes through various means, including open market purchases or redemptions [11].

Core Viewpoint - Lido Merger Sub, Inc. has successfully received tenders and consents for approximately 97.95% of Landsea Homes Corporation's outstanding 8.875% Senior Notes due 2029 as part of a cash tender offer and consent solicitation [1] Group 1: Tender Offer Details - The Company received tenders and consents amounting to $293,848,000 in aggregate principal of the Notes by the deadline [1] - The total consideration for the Notes is $1,044.38 per $1,000 in principal amount, which includes a $50 Early Participation Premium [3] - Holders whose Notes are accepted will also receive accrued and unpaid interest up to the settlement date [5] Group 2: Proposed Amendments - A supplemental indenture was executed to eliminate the "Change of Control Offer" requirement and most restrictive covenants related to the Notes [2] - The Proposed Amendments will only take effect if a majority of the Notes are accepted for purchase [2] Group 3: Conditions and Timeline - The consummation of the Tender Offer is contingent upon the successful completion of the Merger and certain financing conditions [7] - The Merger is expected to close early in the third quarter of 2025, with the Expiration Date of the Tender Offer likely extended until then [7][8] - The Company reserves the right to waive any conditions related to the Tender Offer [7]